Financial Incentives for Smoking Treatment II
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Jun 6, 2019
Trial Information
Current as of November 12, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This study, called Financial Incentives for Smoking Treatment II (FIESTA II), looks at whether giving people money or rewards helps hospitalized smokers quit more often. Adults who smoke will be randomly assigned to one of three groups: (1) goal-directed incentives that reward using proven quitting aids like counseling and medications, (2) outcome-based incentives that reward actually staying smoke-free (verified by a saliva test) and using quitting aids, and (3) enhanced usual care with counseling and access to quitting medications but no incentives. The trial plans to enroll about 1,058 people and will track whether they are abstinent from smoking at 6 months, plus other outcomes like use of quit tools, quality of life, and overall costs and savings over time.
Eligible participants are adults 18 and older who have smoked in the last 30 days, live in the United States with a valid phone number and address, can consent in English or Spanish, and are at least thinking about quitting. Exclusions include those who only use smokeless tobacco, those who are pregnant or breastfeeding, people discharged to an institution, or anyone unable to consent. If you participate, you’ll receive smoking cessation counseling (through Quitline), be encouraged to try nicotine-replacement therapy or other quitting medicines, and some groups may receive financial incentives for quitting or for using evidence-based quitting methods. The study is led by UCLA and NYU Langone Health, with additional partners, and researchers plan to share results after publication. Recruitment began in 2020 and is expected to finish around 2025; results are not available yet.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. age ≥ 18 years
- • 2. smoked tobacco during the prior 30 days,
- • 3. have an active U.S. phone number and address,
- • 4. can provide consent in English or Spanish and
- • 5. are in at least the contemplative stage of change for quitting smoking, as assessed by a single measure, readiness to quit
- Exclusion Criteria:
- • 1. use only smokeless tobacco,
- • 2. are pregnant or breastfeeding,
- • 3. are discharged to an institution (e.g., nursing home, long-term care facility),
- • 4. are unable to provide informed consent, or do not have cognitive ability to enroll or participate in the study
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Los Angeles, California, United States
Patients applied
Trial Officials
Joseph Ladapo, MD, PhD
Principal Investigator
University of California, Los Angeles
Scott Sherman, MD
Principal Investigator
NYU Langone Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials